Meta-analyses of phase 3 randomized controlled trials prove that with aromatase inhibitors, progression-free survival (PFS) is longer, although no significant change in overall survival in postmenopausal women with HR+ advanced breast cancer has been noted (65). Here, CYP19A1 is linked to breast cancer.